Merck & Co. Announced Third Quarter Results

Merck & Co. Third Quarter Performance

Merck & Co. Inc. (NYSE:MRK) is among the long-term stocks that attract investor interest. The third quarter results, released on October 30, demonstrated better-than-expected financial performance. The company’s revenue was $17.3 billion, surpassing analyst estimates of $16.98 billion, while earnings per share came in at $2.58, significantly above the anticipated $2.35.

The oncology division continues to be the main source of the company’s growth, with KEYTRUDA drug sales recorded at $8.1 billion for the quarter. Other oncology drugs also showed good results; WELIREG sales rose by 41% to $196 million, Lynparza sales increased by 12% to $379 million, and Lenvima sales grew by 2% to $258 million.

Additionally, the approval of subcutaneous pembrolizumab (KEYTRUDA QLEX) by the U.S. Food and Drug Administration, which was approved for solid tumors, marked an important regulatory milestone during the quarter. This formulation may enhance the patient experience as it can be administered in just one minute.

On the other hand, Merck & Co. Inc. (NYSE:MRK) faced significant challenges in its vaccines division. GARDASIL sales declined by 25% to $1.7 billion due to a drop in sales in China.

Merck & Co. Inc. is a healthcare company that provides human health pharmaceuticals, veterinary medicines, vaccines, and health management solutions. However, despite its investment potential, it is worth noting that some artificial intelligence stocks offer higher profit potential and possess lower risk.